索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陆寒新,Shailendra,Kumar,等.生物可吸收支架进展及前景[J].国际心血管病杂志,2016,02:75-78.
点击复制

生物可吸收支架进展及前景(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年02期
页码:
75-78
栏目:
综述
出版日期:
2016-03-20

文章信息/Info

Title:
-
作者:
陆寒新; Shailendra; Kumar; Karn; 车文良; 徐亚伟
210000 南京医科大学(陆寒新,徐亚伟); 200072 上海,同济大学附属第十人民医院心脏中心(Shailendra Kumar Karn,车文良)
Author(s):
-
关键词:
生物可吸收支架; 介入治疗; 再狭窄
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.02.004
文献标识码:
-
摘要:
已有系列临床研究证实生物可吸收支架(BVS)的安全性和有效性。与药物洗脱支架相比,BVS的优点是主要不良心脏事件及支架内再狭窄率较低,但在减少支架内血栓方面并无优势,可能与不充分的抗血小板治疗、支架厚度及支架扩张不全有关。该文主要介绍BVS中应用经验较多的Absorb支架。
Abstract:
-

参考文献/References

[1] Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions(ABSORB): a prospective open-label trial[J]. Lancet,2008,371(9616):899-907.
[2] 柯永胜. 药物洗脱支架的临床研究进展[J]. 国际心血管病杂志,2006,33(5):333-337.
[3] Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system(ABSORB): 2-year outcomes and results from multiple imaging methods[J]. Lancet,2009,373(9667):897-910.
[4] Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial[J]. JACC Cardiovasc Interv,2013,6(10):999-1009.
[5] Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes[J]. Circulation, 2010,122(22):2301-2312.
[6] Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months[J]. EuroIntervention,2014,9(11):1271-1284.
[7] Abizaid A, Ribamar Costa J Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled[J]. EuroIntervention,2015,10(12):1396-1401.
[8] Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial[J]. Lancet,2015,385(9962):43-54.
[9] Simsek C, Magro M, Onuma Y, et al. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals(B-SEARCH)[J]. EuroIntervention,2014,10(2):236-240.
[10] Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold(BVS)in real-world practice: the AMC Single Centre Real World PCI Registry[J]. EuroIntervention,2015,10(10):1160-1168.
[11] Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry[J]. EuroIntervention,2015,10(10):1144-1153.
[12] Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'[J]. Eur Heart J,2014,35(12):787-794.
[13] Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes[J]. EuroIntervention,2014,9(9):1036-1041.
[14] Kang SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis[J]. Eur Heart J,2014,35(17):1147-1158.
[15] Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population[J]. Catheter Cardiovasc Interv,2015,85(1):E10-E15.
[16] Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance[J]. JACC Cardiovasc Interv,2014,7(7):741-750.
[17] Wohrle J, Naber C, Schmitz T, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds[J]. EuroIntervention,2015,11(2):149-156.
[18] Rzeszutko L, Siudak Z, Wlodarczak A, et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry[J]. Kardiol Pol,2014,72(12):1394-1399.
[19] Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study[J]. Eur Heart J,2014,35(12):777-786.
[20] Arroyo D, Togni M, Puricel S, et al. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO Ⅱ trial[J]. Trials,2014,15:9.
[21] Gogas BD, Serruys PW, Diletti R, et al. sculVaar response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial[J]. JACC Cardiovasc Interv,2012,5(6):656-665.
[22] Indolfi C, Mongiardo A, Spaccarotella C,et al. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation[J]. Circ Cardiovasc Imaging,2014,7(4):755-757.
[23] Ielasi A, Cortese B, Varricchio A, et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano"(RAI registry)[J]. EuroIntervention,2015,11(2):157-162.
[24] Dudek D, Rzeszutko L, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study[J]. Pol Arch Med Wewn,2014,124(12):669-677.
[25] Brown AJ, McCormick LM, Braganza DM,et al. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation[J]. Catheter Cardiovasc Interv,2014,84(1):37-45.
[26] Gorge G, Haude M, Ge J, et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation[J]. J Am Coll Cardiol,1995,26(3):725-730.
[27] Hur SH, Kitamura K, Morino Y, et al. Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound[J].Am J Cardiol,2001,88(10):1114-1119.
[28] Doi H, Maehara A, Mintz GS, et al. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS Ⅳ, Ⅴ, and Ⅵ and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials[J]. JACC Cardiovasc Interv,2009,2(12):1269-1275.
[29] Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial[J]. J Am Coll Cardiol,2004,43(11):1959-1963.
[30] Di Mario C, Caiazzo G. Biodegradable stents: the golden future of angioplasty?[J]. Lancet,2015,385(9962):10-12.
[31] Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study[J]. J Am Coll Cardiol,2005,45(7):995-998.
[32] Chen JH,Wu YZ,Shen L,et al. First-in-man implantation of the Xinsorb bioresorbable sirolimus-eluting scaffold in China[J].Chin Med J,2015,128(9):1275-1276.

备注/Memo

备注/Memo:
通信作者:徐亚伟,Email:13916698181@139.com
更新日期/Last Update: 2016-03-20